∙ Patients must meet the following criteria for study entry:

• Adults aged ≥18

• Require therapy as determined by the treating physician

• Patients must have adequate organ and bone marrow function:

‣ Absolute neutrophil count (ANC) ≥ 1 x 109/L without growth factor support (filgrastim or pegfilgrastim) for at least 14 days

⁃ Platelet count ≥75 x 109/L, evaluated at least 7 days after last platelet transfusion

⁃ Hemoglobin ≥9.0g/dL, independent of transfusion

⁃ Total bilirubin \< 1.5 x's the upper limit of the normal range (ULN), except Gilbert's disease

⁃ Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \< 3 x's ULN.

⁃ Calculated creatinine clearance according to the Cockcroft-Gault equation. ≥ 40 mL/min

• ECOG PS 0-2

• Ability and willingness to provide signed Informed Consent Form

• Ability and willingness to comply with the requirements of the study protocol

• Measurable disease (defined as ≥ 1.5cm in diameter) In addition, patients must meet the following conditions for enrollment based on whether they have DLBCL or FL.

∙ R/R DLBCL Cohort:

• Histologically confirmed, biopsy-proven diagnosis of DLBCL (as determined by WHO standard classification criteria).

• Please note: Transformed DLBCL patients are eligible, with the exception of Richter's transformation.

• Subjects must have received at least two prior lines of therapy for lymphoma with evidence of disease progression.

• Subjects are eligible if they have progressed after ASCT OR if they are ineligible for ASCT, as determined by their treating physician.

∙ R/R FL Cohort:

• Histologically confirmed, biopsy-proven diagnosis of FL

• Subjects are eligible if they have progressed after two or more lines of therapy for lymphoma or have no satisfactory treatment alternatives